Nomination Committee 2018

Nomination Committee in respect of AGM 2018 in Ascelia Pharma AB (publ)

According to the instruction for Nomination Committee in Ascelia Pharma AB (publ) adopted at the annual general meeting held on 31 October 2017, the Nomination Committee shall consist of four members, representing the three largest shareholders per the end of March, together with the chairman of the board of directors. The “three largest shareholders” refer to the ownership grouped registered or in any other way known shareholders as per the end of March.

Based on the above, the Nomination Committee in respect of the AGM that will be held in Malmö on 23 November 2018 has been established to consist of the following persons together representing approximately 62.5 per cent of the shares and votes in the company:

  • Andreas Segerros, chairman of the Nomination Committee, appointed by Sunstone Life Science Ventures II K/S;
  • Nils Lorentzen, appointed by CMC SPV of 3 April 2017 AB;
  • Håkan Nelson, appointed by Øresund Healthcare Capital K/S; and
  • Peter Benson, chairman of the board of directors.

The Nomination Committee’s proposals will be presented in the notice to the Annual General Meeting 2018 and on the company’s website, www.ascelia.com

Shareholders who wish to submit proposals to the Nomination Committee are welcome to contact the Nomination Committee at the company’s address or alternatively via e-mail kb@ascelia.com. Proposals shall be submitted in due time before the Annual General Meeting, but not later than 19 October 2018, to ensure that the proposals can be considered by the Nomination Committee.

Mangoral

Our lead candidate Mangoral is a liver imaging drug (i.e. a liver specific contrast agent) being developed for detection and localization of potential liver metastases, using Magnetic Resonance Imaging (“MRI”) in patients where use of the current gold standard gadolinium-based contrast agents (“GBCAs”) may be medically inadvisable or cannot be administered. Mangoral is currently ready for Phase III clinical development.

Oncoral

Oncoral is a novel tablet-based formulation of the well-known chemotherapeutic agent irinotecan, intended for the treatment of advanced gastric (stomach) cancer. Irinotecan is today mainly used for treating metastasized colorectal cancer. Although irinotecan is currently not approved for treating gastric cancer in the United States and in the EU, there is off-label use for this indication. Oncoral is currently being evaluated in an investigator sponsored Phase I study.

DEVELOPMENT PLAN

Ascelia has established a development program for lead candidate Mangoral, consisting of a pivotal Phase III efficacy study and two supportive studies. The clinical development strategy for Oncoral, Ascelia´s second drug candidate, is to obtain Phase II data and then to partner for the further development.